Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Herbst, R.S. (Roy S.) | - |
dc.creator | Garon, E.B. (E. B.) | - |
dc.creator | Kim, D.W, (D. W.) | - |
dc.creator | Chul-Cho, B. (B.) | - |
dc.creator | Perez-Gracia, J.L. (Jose Luis) | - |
dc.creator | Han, J.Y. (J. Y.) | - |
dc.creator | Dubos-Arvis, C. (C.) | - |
dc.creator | Majem-Tarruella, M. (Margarita) | - |
dc.creator | Forster, M. (M.) | - |
dc.creator | Monnet, I. (I.) | - |
dc.creator | Novello, S. (S.) | - |
dc.creator | Szalai, Z. (Z.) | - |
dc.creator | Gubens, M.A. (M. A.) | - |
dc.creator | Su, W.C. (W. C.) | - |
dc.creator | Ceresoli, G.L. (G. L.) | - |
dc.creator | Samkari, A. (A.) | - |
dc.creator | Jensen, E.H. (E. H.) | - |
dc.creator | Lubiniecki, G.M (G. M.) | - |
dc.creator | Baas, P. (P.) | - |
dc.date.accessioned | 2023-02-14T09:18:52Z | - |
dc.date.available | 2023-02-14T09:18:52Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Kim, D.W, (D. W.); et al. "Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro". Annals of oncology. 29 (Supl. 10), 2018, 42 | es |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://hdl.handle.net/10171/65452 | - |
dc.description.abstract | In the global, open-label, phase 2/3 study KEYNOTE-010, pembro 10 mg/kg or 2 mg/kg Q3W improved OS vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1% (coprimary analyses) at median follow-up of 13.1 mo. We present long-term results overall, in pts who completed 35 cycles (∼2 y) of pembro, and in pts who received a second course of pembro. | es_ES |
dc.description.sponsorship | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Improved OS | es_ES |
dc.subject | Docetaxel | es_ES |
dc.title | Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.1093/annonc/mdy511.003 | - |
dadun.citation.number | Supl. 10 | es_ES |
dadun.citation.publicationName | Annals of oncology | es_ES |
dadun.citation.startingPage | 42 | es_ES |
dadun.citation.volume | 29 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.